» Articles » PMID: 33423930

Aluminium Adjuvants in Vaccines - A Way to Modulate the Immune Response

Overview
Date 2021 Jan 11
PMID 33423930
Citations 36
Authors
Affiliations
Soon will be listed here.
Abstract

Aluminium salts have been used as adjuvants in vaccines for almost a century, but still no clear understanding of the mechanisms behind the immune stimulating properties of aluminium based adjuvants is recognized. Aluminium adjuvants consist of aggregates and upon administration of a vaccine, the aggregates will be recognized and phagocytosed by sentinel cells such as macrophages or dendritic cells. The adjuvant aggregates will persist intracellularly, maintaining a saturated intracellular concentration of aluminium ions over an extended time. Macrophages and dendritic cells are pivotal cells of the innate immune system, linking the innate and adaptive immune systems, and become inflammatory and antigen-presenting upon activation, thus mediating the initiation of the adaptive immune system. Both types of cell are highly adaptable, and this review will discuss and highlight how the occurrence of intracellular aluminium ions over an extended time may induce the polarization of macrophages into inflammatory and antigen presenting M1 macrophages by affecting the: endosomal pH; formation of reactive oxygen species (ROS); stability of the phagosomal membrane; release of damage associated molecular patterns (DAMPs); and metabolism (metabolic re-programming). This review emphasizes that a persistent intracellular presence of aluminium ions over an extended time has the potential to affect the functionality of sentinel cells of the innate immune system, inducing polarization and activation. The immune stimulating properties of aluminium adjuvants is presumably mediated by several discrete events, however, a persistent intracellular presence of aluminium ions appears to be a key factor regarding the immune stimulating properties of aluminium based adjuvants.

Citing Articles

The spectrum of lysosomal stress and damage responses: from mechanosensing to inflammation.

Scott O, Saran E, Freeman S EMBO Rep. 2025; .

PMID: 40016424 DOI: 10.1038/s44319-025-00405-9.


Next-generation aluminum adjuvants: Immunomodulatory layered double hydroxide NanoAlum reengineered from first-line drugs.

Su Z, Boucetta H, Shao J, Huang J, Wang R, Shen A Acta Pharm Sin B. 2024; 14(11):4665-4682.

PMID: 39664431 PMC: 11628803. DOI: 10.1016/j.apsb.2024.09.012.


Adsorption and Desorption of Immune-Modulating Substances by Aluminium-Based Adjuvants: An Overlooked Feature of the Immune-Stimulating Mechanisms of Aluminium-Based Adjuvants.

Danielsson R, Mile I, Eriksson H Int J Mol Sci. 2024; 25(22).

PMID: 39596470 PMC: 11594729. DOI: 10.3390/ijms252212399.


ASIA Syndrome: State-of-the-Art and Future Perspectives.

Caldarelli M, Rio P, Giambra V, Gasbarrini A, Gambassi G, Cianci R Vaccines (Basel). 2024; 12(10).

PMID: 39460349 PMC: 11511404. DOI: 10.3390/vaccines12101183.


Simplified scalable synthesis of a water-soluble toll-like receptor 2 agonistic lipopeptide adjuvant for use with protein-based viral vaccines.

Brar D, Kaur A, Patil M, Honda-Okubo Y, Petrovsky N, Salunke D Bioorg Chem. 2024; 153:107835.

PMID: 39342891 PMC: 11614683. DOI: 10.1016/j.bioorg.2024.107835.